Testing effectiveness (Phase 2)Study completedNCT06234956
What this trial is testing
Open-label, Multi-centre, Non-Inferiority Study of Safety and Immunogenicity of BIMERVAX for the Prevention of COVID-19 in Adolescents From 12 Years to Less Than 18 Years of Age.
Who this might be right for
SARS CoV 2 Infection
Hipra Scientific, S.L.U 242